Skip to main content

Table 2 Recommended therapy management after index event

From: Evaluation of therapy management and outcome in Takotsubo syndrome

  Study population n = 72
No antiplatelet therapy 9 (4.2%)
 With OAC monotherapy 6
OAC + ASA 3 (4.2%)
 Without temporal recommendation
OAC + Clopidogrel 1 (1.4%)
 With temporal recommendation for 3 months
Monotherapy antiplatelet: 28 (38.9%)
 ASA 25 (34.7%)
  Without temporal recommendation 24
  With temporal recommendation for 3 months 1
 Clopidogrel 2 (2.8%)
  Without temporal recommendation 1
  With temporal recommendation for 6 months 1
 Ticagrelor 1 (1.4%)
  With temporal recommendation for 12 months 1
Dual antiplatelet therapy: 29 (40.3%)
 ASA + Clopidogrel 24 (33.3%)
  Without temporal recommendation 5
  With temporal recommendation: 19
   1 month 2
   3 months 4
   6 months 4
   12 months 8
 ASA + Prasugrel 2 (2.8%)
  Without temporal recommendation 1
  With temporal recommendation for 12 months 1
 ASA + Ticagrelor 3 (4.2%)
  Without temporal recommendation 0
  With temporal recommendation 3
   1 month 1
   3 months 1
   12 months 1
 “Triple” therapy with ASA 2 (2.8%)
  1 month, Clopidogrel + OAC 6 months, OAC monotherapy 1
  1 month, Clopidogrel + OAK 12 months, OAC monotherapy 1
  1. Data is presented as number of patients and percentage
  2. ASA Acetylsalicyl Acid, LWMH low weight molecular heparin, OAC oral anticoagulation